Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone847-871-0377
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.57 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Aptinyx (NASDAQ:APTX) Frequently Asked Questions
What is Aptinyx's stock symbol?
Aptinyx trades on the NASDAQ under the ticker symbol "APTX."
How were Aptinyx's earnings last quarter?
Aptinyx Inc (NASDAQ:APTX) posted its quarterly earnings data on Monday, August, 12th. The company reported ($0.36) EPS for the quarter, beating the Zacks' consensus estimate of ($0.52) by $0.16. The company earned $0.93 million during the quarter, compared to the consensus estimate of $0.95 million. Aptinyx had a negative net margin of 1,504.24% and a negative return on equity of 40.01%. View Aptinyx's Earnings History.
When is Aptinyx's next earnings date?
What price target have analysts set for APTX?
7 brokerages have issued twelve-month target prices for Aptinyx's stock. Their forecasts range from $7.00 to $22.00. On average, they anticipate Aptinyx's share price to reach $13.1667 in the next year. This suggests a possible upside of 229.2% from the stock's current price. View Analyst Price Targets for Aptinyx.
What is the consensus analysts' recommendation for Aptinyx?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx.
What are Wall Street analysts saying about Aptinyx stock?
Here are some recent quotes from research analysts about Aptinyx stock:
- 1. According to Zacks Investment Research, "Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. " (8/16/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and 12-month PT of $12 on APTX. With an initial focus on large indications within chronic pain, there are multiple nervous system disorder opptys for the company’s candidates that have a better safety/tolerability profile relative to historical NMDAr-based treatments like ketamine. Data from pre-clinical models look promising, and important PoC trial data should emerge this year. Valuation Summary We use a discounted NPV revenue calculation that yields ~$10 for NYX-2925 in DPN and ~$2 for pipeline placeholder ($75M total NPV) in fibromyalgia." (4/30/2019)
Has Aptinyx been receiving favorable news coverage?
News coverage about APTX stock has trended negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aptinyx earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Aptinyx.
Are investors shorting Aptinyx?
Aptinyx saw a increase in short interest in August. As of August 31st, there was short interest totalling 668,300 shares, an increase of 17.7% from the July 31st total of 567,600 shares. Based on an average trading volume of 228,600 shares, the days-to-cover ratio is presently 2.9 days. Approximately 4.9% of the shares of the company are short sold. View Aptinyx's Current Options Chain.
Who are some of Aptinyx's key competitors?
Some companies that are related to Aptinyx include Akero Therapeutics (AKRO), Lannett (LCI), Intra-Cellular Therapies (ITCI), Myovant Sciences (MYOV), Viking Therapeutics (VKTX), Retrophin (RTRX), Basilea Pharmaceutica (BPMUF), Milestone Pharmaceuticals (MIST), ImmunoGen (IMGN), Kiniksa Pharmaceuticals (KNSA), Urogen Pharma (URGN), Aptorum Group (APM), Progenics Pharmaceuticals (PGNX), Dermira (DERM) and Syros Pharmaceuticals (SYRS).
What other stocks do shareholders of Aptinyx own?
Who are Aptinyx's key executives?
Aptinyx's management team includes the folowing people:
- Dr. Norbert G. Riedel, Pres, CEO & Director (Age 61)
- Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 68)
- Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)
- Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 43)
- Ms. Betty Y. Jang, VP of Legal Affairs (Age 50)
When did Aptinyx IPO?
(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
Who are Aptinyx's major shareholders?
Aptinyx's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.17%), BlackRock Inc. (1.68%), Marshall Wace LLP (0.91%), Morgan Stanley (0.52%), JPMorgan Chase & Co. (0.45%) and Northern Trust Corp (0.43%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Robert J Hombach and Torsten M Madsen. View Institutional Ownership Trends for Aptinyx.
Which institutional investors are selling Aptinyx stock?
APTX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, JPMorgan Chase & Co., Canada Pension Plan Investment Board, Charles Schwab Investment Management Inc., Northern Trust Corp and Alambic Investment Management L.P.. View Insider Buying and Selling for Aptinyx.
Which institutional investors are buying Aptinyx stock?
APTX stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Jane Street Group LLC, Paloma Partners Management Co, Acadian Asset Management LLC, Marshall Wace LLP, Citadel Advisors LLC, Weiss Asset Management LP and Jacobs Levy Equity Management Inc.. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Robert J Hombach and Torsten M Madsen. View Insider Buying and Selling for Aptinyx.
How do I buy shares of Aptinyx?
Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aptinyx's stock price today?
One share of APTX stock can currently be purchased for approximately $4.00.
How big of a company is Aptinyx?
Aptinyx has a market capitalization of $134.24 million and generates $6.57 million in revenue each year. The company earns $-53,280,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. View Additional Information About Aptinyx.
What is Aptinyx's official website?
How can I contact Aptinyx?
Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]
MarketBeat Community Rating for Aptinyx (NASDAQ APTX)
MarketBeat's community ratings are surveys of what our community members think about Aptinyx and other stocks. Vote "Outperform" if you believe APTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
